TScan Therapeutics, Inc. (TCRX) Misses Q4 EPS by 1c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $670 thousand versus the consensus estimate of $1.51 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Hertz Global amends voting agreement with CK Amarillo after lawsuit
• Medtronic (MDT) Declares $0.72 Quarterly Dividend; 3.1% Yield